BACKGROUND: It is well known that the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) correlates with progression of liver fibrosis. However, there is little information on the impact of aging on hepatocarcinogenesis. The aim of this study was to elucidate the clinicopathological features of elderly patients with HCV-related HCC. METHODS: The study subjects were 693 consecutive patients newly diagnosed with HCC with anti-HCV. First, we divided them into a younger group (<70 years) and an elderly group (> or =70 years) and compared clinicopathological features between the two groups. Next, we selected pure HCV-related HCC patients by excluding the patients with other probable factors for hepatocarcinogenesis (anti-HBc, interferon therapy, and alcohol) and compared the two groups again. RESULTS: Higher platelet count, lower male/female ratio, lower rate of habitual alcohol consumption, and better Child-Pugh class were recognized in the elderly group thant the younger group, statistically. In 133 cases of hepatic resection, fibrosis stage was lower in the elderly than the younger group. After selection of pure HCV-related HCC patients, in a stepwise multi variate analysis, male sex and platelet count <10 x 10(4)/mm3 were significant variables associated with age <70. Regarding the latency period to HCC development, the patients who received a blood transfusion at an older age developed HCC sooner despite their lower grade of fibrosis. CONCLUSIONS: The elderly patients developed HCC more often, despite their lower grade of fibrosis, compared with the younger patients. In addition to fibrosis, aging could be a factor affecting HCV-related hepatocarcinogenesis.
BACKGROUND: It is well known that the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) correlates with progression of liver fibrosis. However, there is little information on the impact of aging on hepatocarcinogenesis. The aim of this study was to elucidate the clinicopathological features of elderly patients with HCV-related HCC. METHODS: The study subjects were 693 consecutive patients newly diagnosed with HCC with anti-HCV. First, we divided them into a younger group (<70 years) and an elderly group (> or =70 years) and compared clinicopathological features between the two groups. Next, we selected pure HCV-related HCC patients by excluding the patients with other probable factors for hepatocarcinogenesis (anti-HBc, interferon therapy, and alcohol) and compared the two groups again. RESULTS: Higher platelet count, lower male/female ratio, lower rate of habitual alcohol consumption, and better Child-Pugh class were recognized in the elderly group thant the younger group, statistically. In 133 cases of hepatic resection, fibrosis stage was lower in the elderly than the younger group. After selection of pure HCV-related HCC patients, in a stepwise multi variate analysis, male sex and platelet count <10 x 10(4)/mm3 were significant variables associated with age <70. Regarding the latency period to HCC development, the patients who received a blood transfusion at an older age developed HCC sooner despite their lower grade of fibrosis. CONCLUSIONS: The elderly patients developed HCC more often, despite their lower grade of fibrosis, compared with the younger patients. In addition to fibrosis, aging could be a factor affecting HCV-related hepatocarcinogenesis.
Authors: E Silini; R Bottelli; M Asti; S Bruno; M E Candusso; S Brambilla; F Bono; G Iamoni; C Tinelli; M U Mondelli; G Ideo Journal: Gastroenterology Date: 1996-07 Impact factor: 22.682
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: G Sbolli; A R Zanetti; E Tanzi; L Cavanna; G Civardi; F Fornari; M Di Stasi; L Buscarini Journal: J Med Virol Date: 1990-03 Impact factor: 2.327
Authors: F Hasan; L J Jeffers; M De Medina; K R Reddy; T Parker; E R Schiff; M Houghton; Q L Choo; G Kuo Journal: Hepatology Date: 1990-09 Impact factor: 17.425
Authors: F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret Journal: Gut Date: 2000-07 Impact factor: 23.059
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: W Ohishi; M Kitamoto; H Aikata; K Kamada; Y Kawakami; H Ishihara; M Kamiyasu; T Nakanishi; S Tazuma; K Chayama Journal: Scand J Gastroenterol Date: 2003-08 Impact factor: 2.423
Authors: Kathryn L Nash; Tracy Woodall; Ashley S M Brown; Susan E Davies; Graeme J M Alexander Journal: World J Gastroenterol Date: 2010-08-28 Impact factor: 5.742
Authors: Jian Xing; Philip R Spradling; Anne C Moorman; Scott D Holmberg; Eyasu H Teshale; Loralee B Rupp; Stuart C Gordon; Mei Lu; Joseph A Boscarino; Mark A Schmidt; Connie M Trinacty; Fujie Xu Journal: Dig Dis Sci Date: 2017-09-30 Impact factor: 3.199